Current advances in porous organic nanoplatforms for tumor theranostics

Qi, Wanhao; Liu, Bin; Li, Yian; Liu, Zhu; Rui, Shiqiao; Feng, Shuaipeng; Lu, Junya; Wang, Siling; Zhao, Qinfu

doi:10.1016/j.cej.2024.150448

Cited by 2 publications

(2 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The levels of NTR expression in these tumors are significantly higher than the basal levels found in healthy cells, often by several orders of magnitude. This differential expression underpins the selective activation of NTR-targeted therapies, enhancing therapeutic efficacy while minimizing off-target effects ( Williams et al, 2015 ; Hu X. et al, 2022 ; Qi et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

“…Tumor theranostics, which combines therapeutic and diagnostic functions in a single platform, represents a promising strategy for improving cancer treatment outcomes ( Hapuarachchige and Artemov, 2020 ; Jiang et al, 2021a ; Hu X. et al, 2022 ; Wu D. et al, 2022 ; Wang et al, 2022 ; Zhao et al, 2022 ; Zhang et al, 2023a ; Bose et al, 2023 ; Qi et al, 2024 ). Nitroreductase activable agents have emerged as a novel approach in tumor theranostics, harnessing the enzymatic activity of nitroreductases to selectively target and treat cancer cells while enabling real-time imaging of treatment response ( Li et al, 2024a ; Morsby et al, 2024 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Shang,

Yu,

Wang

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Nitroreductase activable agents offer a personalized and targeted approach to cancer theranostics by selectively activating prodrugs within the tumor microenvironment. These agents enable non-invasive tumor imaging, image-guided drug delivery, and real-time treatment monitoring. By leveraging the enzymatic action of tumor-specific nitroreductase enzymes, cytotoxic drugs are delivered directly to cancer cells while minimizing systemic toxicity. This review highlights the key features, mechanisms of action, diagnostic applications, therapeutic potentials, and future directions of nitroreductase activable agents for tumor theranostics. Integration with imaging modalities, advanced drug delivery systems, immunotherapy combinations, and theranostic biomarkers shows promise for optimizing treatment outcomes and improving patient survival in oncology. Continued research and innovation in this field are crucial for advancing novel theranostic strategies and enhancing patient care. Nitroreductase activable agents represent a promising avenue for personalized cancer therapy and have the potential to transform cancer diagnosis and treatment approaches.

show abstract

Section: Introductionmentioning

confidence: 99%